Are AIs for Breast Cancer Linked With Increased Myocardial Infarction Risk?
This video examines a study that looked at whether aromatase inhibitors are associated with higher myocardial infarction risk in breast cancer patients.
In this video, Sailaja Kamaraju, MD, of the Medical College of Wisconsin, discusses a study that looked at whether aromatase inhibitors (AIs) are associated with higher myocardial infarction risk in breast cancer patients.
The study looked at 5,648 women (67 years and older) from the Surveillance, Epidemiology, and End Results–Medicare (SEER) database with stages I–III breast cancer who were treated with either AIs (n = 4,690) or tamoxifen (n = 958). With over 2 years follow-up there were 22 deaths from myocardial infarction (251 total cases), with 476 deaths from other causes.
Recent Videos
Related Content
![TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fbb58c5f3c3692dc35c19320bb63c3df864f9b79b-1500x722.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC")
Radhika Appaya;Paolo Tarantino, MD;Hope S. Rugo, MD;Guiseppe Curigliano;Joyce O’Shaughnessy, MD;Wolfgang Janni;Komal Jhaveri;Jason Mouabbi;Adam M. Brufsky, MD, PhD;Erika P. Hamilton, MD;Ruth M. O’Regan; Julia Kim;Liz Santarsiero;Murat Akdere;Fen Ye;Henry Owusu;Stephanie L. Graff, MD
June 20th 2025Article
